Skip to main content

Transplantation, Lung Rejection

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Kamada
KamadaIsrael - Negev
1 program
1
GLASSIA® and Institution standard of carePhase 21 trial
Active Trials
NCT02614872Completed30Est. May 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
KamadaGLASSIA® and Institution standard of care

Clinical Trials (1)

Total enrollment: 30 patients across 1 trials

NCT02614872KamadaGLASSIA® and Institution standard of care

Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation

Start: Jul 2016Est. completion: May 201930 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.